All
Patient Enrollment Expands in Trial Evaluating Novel Drug in Breast Cancer
August 12th 2022After findings from an early-phase trial showed that the novel drug was associated with anti-tumor activity, investigators decided to continue enrolling more patients with ER-positive, HER2-negative metastatic breast cancer.